Delivering Safe and Effective Blood Products for Patients

Cerus Final Intercept United States 3

We invite you to join us at the following events during the upcoming AABB Annual Meeting in Anaheim, CA.

 symposium header

Symposium Description:

Since attaining FDA approval in late 2014, pathogen reduction has gained increasing momentum in the US as demonstrated by industry news, as well as the adoption of the INTERCEPT Blood System by US blood centers. Blood centers strive to deliver safe, efficacious products, while hospitals value timely delivery of the right products to meet patient needs. This symposium examines the role that pathogen reduction plays in meeting such needs. The US experience to date with the INTERCEPT Blood System will be discussed, including potential operational efficiencies gained, and the value that INTERCEPT-treated components could provide to hospitals and their patients. Talks will be followed by an interactive panel discussion.

The symposium will be followed by a networking reception, allowing time for continued discussion with the program speakers, panelists, and attendees.


Richard J. Benjamin, MD, PhD, FRCPath – Chairman
Chief Medical Officer
Cerus Corporation
Concord, CA

James P. AuBuchon, MD
President and CEO
Bloodworks Northwest
Seattle, WA

Joanne Becker, MD
Clinical Chief, Division of Laboratory Medicine,
Department of Pathology and Laboratory Medicine
Medical Director, Blood Bank and Therapeutic Apheresis Unit
Roswell Park Cancer Institute
Buffalo, NY


Patricia Kopko, MD
Director of Transfusion Medicine Associate Director of the Immunogenetics and Transplantation Laboratory
University of California, San Diego School of Medicine
San Diego, CA

James R. Stubbs, MD
Chair, Division of Transfusion Medicine
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

cryo header

Presentation Description:

Creative Cryo: Exploring fibrinogen replacement therapies, advantages and disadvantages

Fibrinogen replacement therapy is typically indicated for the prophylaxis and treatment of hemorrhage such as in liver failure, cardiac surgery, and massive transfusion in trauma. Main sources of fibrinogen are fresh frozen plasma, cryoprecipitate and fibrinogen concentrate. In this booth talk, Dr. Nascimento will present an overview of the use of such therapies, as well as their advantages and disadvantages. The potential role of pathogen reduction in producing plasma-derived products will also be discussed.


Barto Nascimento, MD
General Surgery - Trauma Program
Sunnybrook Health Sciences Centre
Assistant Professor, Department of Surgery
University of Toronto
Toronto, Ontario, Canada


Attend this presentation and you will be entered into a raffle to recieve a gift certificate for the AABB Marketplace. Drawing to be held following conclusion of talk. Must be present to win.

Pathogen Reduction Poster and Oral Presentations

Don’t miss the following pathogen reduction oral and poster presentations!

Monday, October 26, 2015 | 4:30–4:45 PM | Inventory Management, Storage and Distribution
  • Oral-A18-030H Implementation and Optimization of the INTERCEPT Blood System for Platelets and Plasma in a US Blood Center (Nare, C et al.)

Saturday, October 24, 2015 | Noon- 2:00 PM | Abstract Poster Luncheon (Meet the authors)
  • Poster-SP39 In Vitro Evaluation of Platelets in PAS-3 Prepared with the INTERCEPT Blood System (Shaz, B et al.)
  • Poster-SP55 Frozen Stability of INTERCEPT FFP and PF24 (Waldhaus, K et al.)

Cerus Booth

The Cerus /INTERCEPT Booth #480 will be located in the main AABB Exhibition hall. 




Our monthly pathogen reduction newsletter is designed to provide readers with the most up-to-date information related to the INTERCEPT Blood System, pathogen reduction system – the first FDA approved pathogen reduction system.

In each issue you can look forward to:

  • Industry and product news
  • Summaries of recent publications
  • Suggested reading list
  • Calendar of events, including upcoming conferences and educational activities

Sign up today!

Please click here to join our mailing list today.